Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis

Keita Kirito, Shinichiro Okamoto, Kohshi Ohishi, Tetsuzo Tauchi, Hiroshi Handa, Shigeki Saito, Katsuto Takenaka, Kazuya Shimoda, Kenji Oritani, Koichi Akashi, Hikaru Okada, Taro Amagasaki, Kazuyuki Suzuki, Toshio Yonezu, Norio Komatsu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Ruxolitinib, a potent JAK1/JAK2 inhibitor, improved splenomegaly and myelofibrosis-associated symptoms and prolonged survival compared with placebo and best available therapy in the phase 3 COMFORT studies. Although cytopenias were the most common adverse events associated with ruxolitinib treatment, a COMFORT-I analysis showed that they were managed effectively with dose modifications, without a negative impact on the efficacy of ruxolitinib. Subsequently, studies A2202 and AJP01 showed that ruxolitinib is an effective treatment for Japanese patients with myelofibrosis. We conducted a pooled analysis of these two studies (N = 81) to evaluate the association between ruxolitinib dose and changes in spleen volume or symptoms in Japanese patients. Most patients began treatment at 15 or 20 mg twice daily (BID); 70% received a final titrated dose ≥ 10 mg BID. Overall, 91% of patients exhibited spleen volume reductions; patients with final titrated doses ≥ 10 mg BID had larger spleen volume reductions. Similarly, 83% of patients showed improvements in symptom scores; those with a final titrated dose of 20 or 25 mg BID had the greatest reductions. Consistent with COMFORT-I, this pooled analysis indicates that, despite dose adjustments, ruxolitinib provides spleen and symptom control in Japanese patients, with higher doses associated with better responses.

Original languageEnglish
Pages (from-to)92-97
Number of pages6
JournalInternational journal of hematology
Volume107
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Primary Myelofibrosis
Spleen
Splenomegaly
Therapeutics
INCB018424
Placebos
Survival

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Kirito, K., Okamoto, S., Ohishi, K., Tauchi, T., Handa, H., Saito, S., ... Komatsu, N. (2018). Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. International journal of hematology, 107(1), 92-97. https://doi.org/10.1007/s12185-017-2332-z

Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. / Kirito, Keita; Okamoto, Shinichiro; Ohishi, Kohshi; Tauchi, Tetsuzo; Handa, Hiroshi; Saito, Shigeki; Takenaka, Katsuto; Shimoda, Kazuya; Oritani, Kenji; Akashi, Koichi; Okada, Hikaru; Amagasaki, Taro; Suzuki, Kazuyuki; Yonezu, Toshio; Komatsu, Norio.

In: International journal of hematology, Vol. 107, No. 1, 01.01.2018, p. 92-97.

Research output: Contribution to journalArticle

Kirito, K, Okamoto, S, Ohishi, K, Tauchi, T, Handa, H, Saito, S, Takenaka, K, Shimoda, K, Oritani, K, Akashi, K, Okada, H, Amagasaki, T, Suzuki, K, Yonezu, T & Komatsu, N 2018, 'Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis', International journal of hematology, vol. 107, no. 1, pp. 92-97. https://doi.org/10.1007/s12185-017-2332-z
Kirito, Keita ; Okamoto, Shinichiro ; Ohishi, Kohshi ; Tauchi, Tetsuzo ; Handa, Hiroshi ; Saito, Shigeki ; Takenaka, Katsuto ; Shimoda, Kazuya ; Oritani, Kenji ; Akashi, Koichi ; Okada, Hikaru ; Amagasaki, Taro ; Suzuki, Kazuyuki ; Yonezu, Toshio ; Komatsu, Norio. / Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. In: International journal of hematology. 2018 ; Vol. 107, No. 1. pp. 92-97.
@article{3d4627cc20fd4a8a88e2c2dbb6d36847,
title = "Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis",
abstract = "Ruxolitinib, a potent JAK1/JAK2 inhibitor, improved splenomegaly and myelofibrosis-associated symptoms and prolonged survival compared with placebo and best available therapy in the phase 3 COMFORT studies. Although cytopenias were the most common adverse events associated with ruxolitinib treatment, a COMFORT-I analysis showed that they were managed effectively with dose modifications, without a negative impact on the efficacy of ruxolitinib. Subsequently, studies A2202 and AJP01 showed that ruxolitinib is an effective treatment for Japanese patients with myelofibrosis. We conducted a pooled analysis of these two studies (N = 81) to evaluate the association between ruxolitinib dose and changes in spleen volume or symptoms in Japanese patients. Most patients began treatment at 15 or 20 mg twice daily (BID); 70{\%} received a final titrated dose ≥ 10 mg BID. Overall, 91{\%} of patients exhibited spleen volume reductions; patients with final titrated doses ≥ 10 mg BID had larger spleen volume reductions. Similarly, 83{\%} of patients showed improvements in symptom scores; those with a final titrated dose of 20 or 25 mg BID had the greatest reductions. Consistent with COMFORT-I, this pooled analysis indicates that, despite dose adjustments, ruxolitinib provides spleen and symptom control in Japanese patients, with higher doses associated with better responses.",
author = "Keita Kirito and Shinichiro Okamoto and Kohshi Ohishi and Tetsuzo Tauchi and Hiroshi Handa and Shigeki Saito and Katsuto Takenaka and Kazuya Shimoda and Kenji Oritani and Koichi Akashi and Hikaru Okada and Taro Amagasaki and Kazuyuki Suzuki and Toshio Yonezu and Norio Komatsu",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s12185-017-2332-z",
language = "English",
volume = "107",
pages = "92--97",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis

AU - Kirito, Keita

AU - Okamoto, Shinichiro

AU - Ohishi, Kohshi

AU - Tauchi, Tetsuzo

AU - Handa, Hiroshi

AU - Saito, Shigeki

AU - Takenaka, Katsuto

AU - Shimoda, Kazuya

AU - Oritani, Kenji

AU - Akashi, Koichi

AU - Okada, Hikaru

AU - Amagasaki, Taro

AU - Suzuki, Kazuyuki

AU - Yonezu, Toshio

AU - Komatsu, Norio

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Ruxolitinib, a potent JAK1/JAK2 inhibitor, improved splenomegaly and myelofibrosis-associated symptoms and prolonged survival compared with placebo and best available therapy in the phase 3 COMFORT studies. Although cytopenias were the most common adverse events associated with ruxolitinib treatment, a COMFORT-I analysis showed that they were managed effectively with dose modifications, without a negative impact on the efficacy of ruxolitinib. Subsequently, studies A2202 and AJP01 showed that ruxolitinib is an effective treatment for Japanese patients with myelofibrosis. We conducted a pooled analysis of these two studies (N = 81) to evaluate the association between ruxolitinib dose and changes in spleen volume or symptoms in Japanese patients. Most patients began treatment at 15 or 20 mg twice daily (BID); 70% received a final titrated dose ≥ 10 mg BID. Overall, 91% of patients exhibited spleen volume reductions; patients with final titrated doses ≥ 10 mg BID had larger spleen volume reductions. Similarly, 83% of patients showed improvements in symptom scores; those with a final titrated dose of 20 or 25 mg BID had the greatest reductions. Consistent with COMFORT-I, this pooled analysis indicates that, despite dose adjustments, ruxolitinib provides spleen and symptom control in Japanese patients, with higher doses associated with better responses.

AB - Ruxolitinib, a potent JAK1/JAK2 inhibitor, improved splenomegaly and myelofibrosis-associated symptoms and prolonged survival compared with placebo and best available therapy in the phase 3 COMFORT studies. Although cytopenias were the most common adverse events associated with ruxolitinib treatment, a COMFORT-I analysis showed that they were managed effectively with dose modifications, without a negative impact on the efficacy of ruxolitinib. Subsequently, studies A2202 and AJP01 showed that ruxolitinib is an effective treatment for Japanese patients with myelofibrosis. We conducted a pooled analysis of these two studies (N = 81) to evaluate the association between ruxolitinib dose and changes in spleen volume or symptoms in Japanese patients. Most patients began treatment at 15 or 20 mg twice daily (BID); 70% received a final titrated dose ≥ 10 mg BID. Overall, 91% of patients exhibited spleen volume reductions; patients with final titrated doses ≥ 10 mg BID had larger spleen volume reductions. Similarly, 83% of patients showed improvements in symptom scores; those with a final titrated dose of 20 or 25 mg BID had the greatest reductions. Consistent with COMFORT-I, this pooled analysis indicates that, despite dose adjustments, ruxolitinib provides spleen and symptom control in Japanese patients, with higher doses associated with better responses.

UR - http://www.scopus.com/inward/record.url?scp=85030721793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030721793&partnerID=8YFLogxK

U2 - 10.1007/s12185-017-2332-z

DO - 10.1007/s12185-017-2332-z

M3 - Article

C2 - 28986762

AN - SCOPUS:85030721793

VL - 107

SP - 92

EP - 97

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -